Drawing for NEUROTECH

USPTO serial 75423889

NEUROTECH

Reviewed by CopyMark Law Group

Reg. 2284709Status 710
Filing date
Status date
Registration date
Oct 12, 1999
Examiner
CHICOSKI, JENNIFER D
Law office
SCANNING ON DEMAND

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with NEUROTECH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

RAYMOND O LINKER JR

BELL SELTZER PARK & GIBSONP O BOX 34009CHARLOTTE, NC 28234

Goods and services

ClassDescriptionStatusFirst use
001Biological and biotechnological preparations, namely, polypeptides and precursors for in vitro genetic engineering use and cellular engineering and transgenic use, culture medium for micro-organisms, cells or tissues; and test and diagnostic preparations for scientific useSECTION 8 - CANCELLED—
005Pharmaceutical and veterinary preparations for use in the treatment of cancer, heart diseases, vascular diseases, nervous system diseases; neurodegenerative diseases, psychiatric diseases, ophthalmic diseases; sanitary preparations in the nature of sanitizers for household, hospital, institutional or industrial use; biological and biotechnological preparations for therapeutic use, namely, cellular and genetherapy systems, peptide delivery systems, drugs for the treatment of cancer, heart diseases, vascular diseases, nervous system diseases; neurodegenerative diseases, psychiatric diseases, ophthalmic diseasesSECTION 8 - CANCELLED—
042scientific research and medical laboratory services, namely, development of formulated preparations, diagnostic reagents for application in cancer, detection of sites of angiogenesis, vascular and cerebral diseases in the pharmaceutical and biotechnological fieldsSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 11, 2006CFITCASE FILE IN TICRS—
Jul 22, 2006C8..CANCELLED SEC. 8 (6-YR)—
Oct 12, 1999R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 20, 1999PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 18, 1999NPUBNOTICE OF PUBLICATION—
Apr 9, 1999CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 17, 19991.BDSec. 1(B) CLAIM DELETED—
Mar 17, 1999CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 16, 1998CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Sep 11, 1998DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance